Deadline: 20-Mar-25
The Pfizer is currently accepting proposals to support non-interventional Investigator Sponsored Research projects that will advance the understanding of IB6 patterns of expression and clinical outcomes in NSCLC or explore sigvotatug vedotin’s preclinical activity.
Project Types
- Organizations are invited to submit proposals for studies that fall into 1 of the following 2 categories:
- Noninterventional, (retrospective or prospective studies) looking at integrin beta-6 (IB6) patterns of expression and clinical outcomes in NSCLC
- Preclinical investigator-sponsored research exploring of sigvotatug vedotin’s preclinical activity in relevant tumor models
Area of Interest
- This Research Grant RFP is seeking proposals in two types of non interventional research areas
- Category 1: Noninterventional, (retrospective or prospective studies) looking at integrin beta-6 (IB6) patterns of expression and clinical outcomes in NSCLC
- Pfizer’s interest is to better understand the following regarding IB6 expression:
- Real-world prevalence and patterns of expression in IB6 high vs low expressors overall and in key subgroups (examples include histology, line of therapy, stage of disease, geographic / ethnic background, AGA population, age, gender, body weight, smoking status, and comorbidities)
- Potential impact of IB6 expression on prognosis and other clinical outcomes
- Grant recipients are expected to have access to a tumor bank for retrospective analyses or are able to prospectively collect tumor samples
- To test for IB6 expression, grant recipients must be able to send samples (core-needle biopsies and/or resections; FNAB or cell blocks not supported) to a US-based clinical diagnostics laboratory which has been authorized and trained on a proprietary IB6 IHC assay to provide IB6 staining and analysis
- Pfizer’s interest is to better understand the following regarding IB6 expression:
- Category 2: Preclinical investigator-sponsored research (not limited to NSCLC)
- Exploration of sigvotatug vedotin’s preclinical activity in relevant tumor models
- Investigation of potential immune modulatory effects of sigvotatug vedotin (an investigational IB6- directed ADC) in preclinical tumor models
- Category 1: Noninterventional, (retrospective or prospective studies) looking at integrin beta-6 (IB6) patterns of expression and clinical outcomes in NSCLC
Funding Information
- Individual projects requesting up to $200,000 will be considered.
- 18-month suggested project length (may be shorter or longer).
Eligibility Criteria
- Geographic Scope/Location of Project/Study: Global
- Applicant Eligibility Criteria
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a terminal degree in Pharmacy, Social Work, or other relevant discipline.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc.
For more information, visit Pfizer.